Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents

Ummugulsum Can; Muammer Buyukinan; Asuman Guzelant; Ayse Ugur; Adnan Karaibrahimoglu; Sukrıye Yabancıun

doi:10.1515/jpem-2016-0136

Article

Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents

Ummugulsum Can , Muammer Buyukinan , Asuman Guzelant , Ayse Ugur , Adnan Karaibrahimoglu and Sukrıye Yabancıun

Published/Copyright: October 18, 2016

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Pediatric Endocrinology and Metabolism Volume 29 Issue 11

Abstract

Background:

Metabolic syndrome (MetS) is a chronic and multifactorial syndrome characterized by a low-grade chronic inflammation, and a major risk factor for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). In our study, we aimed to investigate the serum levels of high sensitive C-reactive protein (hs-CRP), haptoglobin (Hp), α₂-macroglobulin (α₂-MG), platelet factor-4 (PF-4), fetuin-A, serum amyloid P (SAP) and α₁-acid glycoprotein (AGP) in an adolescent population with MetS.

Methods:

This study was performed in 43 (18 males, 25 females) MetS adolescents between the ages of 13 and 17 years (14.70±1.15) and 43 lean controls were matched for age and sex. The serum levels of Hp, α₂-MG, PF-4, fetuin-A, SAP and AGP were measured by using a multi-ELISA technique.

Results:

Serum Hp, fetuin-A (p<0.01) and PF-4, hs-CRP, SAP, AGP (p<0.001) values of the MetS subjects were significantly higher than those of the controls. No difference was found in serum α₂-MG levels between the MetS and control groups (p=0.184).

Conclusions:

This finding suggests the possibility of using these markers in diagnosis of MetS in adolescents to prevent future complications.

Keywords: fetuin-A; haptoglobin; α2-macroglobulin; metabolic syndrome; platelet factor-4; serum amyloid P

Corresponding author: Ummugulsum Can, MD, Konya Eğitim Araştırma Hastanesi, Hacışaban Mahallesi, Yeni Meram Caddesi, No:74 Karatay- Konya, Turkey, Phone: 0 332/2211000, Fax: 0 332/3236723, Mobile phone: 05427271671

Acknowledgments

This study was financially supported by Konya Education and Research Hospital.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. All patients were examined by MB. Data analyses were performed by UC, SY and AG in the Department of Biochemistry in Konya Education and Research Hospital. Study design, data interpretation, literature search and generation of figures were performed by UC. Editing the manuscript was by UC and AU. Statistical analyses was performed by AK.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009;119:628–47.10.1161/CIRCULATIONAHA.108.191394Search in Google Scholar PubMed

2. Vandevyver S, Dejager L, Vandenbroucke RE, Libert C. An acute phase protein ready to go therapeutic for sepsis. EMBO Mol Med 2014;6:2–3.10.1002/emmm.201303524Search in Google Scholar PubMed PubMed Central

3. Shachor-Meyouhas Y, Pillar G, Shehadeh N. Uncontrolled type 1 diabetes mellitus and endothelial dysfunction in adolescents. Isr Med Assoc J 2007;9:637–40.Search in Google Scholar

4. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57:1702–6.10.2337/db08-0095Search in Google Scholar PubMed

5. Abu El-Asrar AM, Mohammad G, Nawaz MI, Abdelsaid M, Siddiquei MM, et al. The chemokine platelet factor-4 variant (PF-4var)/CXCL4L1 ınhibits diabetes-ınduced blood-retinal barrier breakdown. Invest Ophthalmol Vis Sci 2015;56:1956–64.10.1167/iovs.14-16144Search in Google Scholar PubMed PubMed Central

6. Wohl H. Platelet markers of thromboembolic disease. West J Med 1981;135:19–24.Search in Google Scholar

7. Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. J Leukoc Biol 2014;96:739–43.10.1189/jlb.1MR0114-068RSearch in Google Scholar PubMed PubMed Central

8. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:352–9.10.5507/bp.2015.018Search in Google Scholar PubMed

9. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, et al. Hyperglycemia induced production of acute phase reactants in adipose tissue. J Biol Chem 2001;276:42077–83.10.1074/jbc.M107101200Search in Google Scholar PubMed

10. Wendt AS, Jefferds ME, Perrine CG, Halleslevens P, Sullivan KM. Obese women less likely to have low serum ferritin, Nicaragua. Public Health Nutr 2015;18:736–41.10.1017/S1368980014000755Search in Google Scholar PubMed PubMed Central

11. Zimmet P, Alberti K, George MM, Kaufman F, Tajima N, et al. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007;8:299–306.10.1111/j.1399-5448.2007.00271.xSearch in Google Scholar PubMed

12. Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, et al. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr 2006;95:1635–41.10.1080/08035250600652013Search in Google Scholar PubMed

13. Bundak R, Furman A, Gunoz H, Darendeliler F, Bas F, et al. Body mass index references for Turkish children. Acta Paediatr 2006;95:194–8.10.1080/08035250500334738Search in Google Scholar

14. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.10.1136/adc.45.239.13Search in Google Scholar

15. Hatipoglu N, Ozturk A, Mazicioglu MM, Kurtoglu S, Seyhan S, et al. Waist circumference percentiles for 7–17 year old Turkish children and adolescents. Eur J Pediatr 2008;167:383–9.10.1007/s00431-007-0502-3Search in Google Scholar

16. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555–76.10.1542/peds.114.S2.555Search in Google Scholar

17. Arslan N, Erdur B, Aydin A. Hormones and cytokines in childhood obesity. Indian Pediatr 2010;47:829–39.10.1007/s13312-010-0142-ySearch in Google Scholar

18. Bogdanski P, Chyrek R, Pupek-Musialik D, Jablecka A. Evaluation of selected acute phase proteins in patients with metabolic syndrome. Pol Merkur Lekarski 2006;21:12–4.Search in Google Scholar

19. Badawi A, Klip A, Haddad P, Cole DE, Bailo BG, et al. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010;3:173–86.10.2147/DMSO.S9089Search in Google Scholar

20. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 2002;40:1984–90.10.1016/S0735-1097(02)02534-2Search in Google Scholar

21. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson K-F, et al. Inflammation sensitive plasma proteins, diabetes, and incidence of myocardial infarction and stroke. Diabetes 2003;52:442–7.10.2337/diabetes.52.2.442Search in Google Scholar PubMed

22. Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, et al. Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab 2004;89:2678–83.10.1210/jc.2003-031965Search in Google Scholar PubMed

23. Lisi S, Gamucci O, Vottari T, Scabia G, Funicello M, et al. Obesity-associated hepatosteatosis and impairment of glucose homeostasis are attenuated by haptoglobin deficiency. Diabetes 2011;60:2496–505.10.2337/db10-1536Search in Google Scholar PubMed PubMed Central

24. Priya MT, Sheriff DS. A preliminary study of inflammatory markers in non-alcoholic steatohepatitis patients. Libyan J Med 2010;5:1–4.10.3402/ljm.v5i0.5071Search in Google Scholar

25. Bell LN, Lee L, Saxena R, Bemis KG, Wang M, et al. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol 2010;298:G746–54.10.1152/ajpgi.00485.2009Search in Google Scholar

26. Swiatkowska-Stodulska R, Babinska A, Skibowska-Bielinska A, Sworczak K. Assessment of alpha1-antitrypsin and alpha2-macroglobulin levels in obese patients. Pol Arch Med Wewn 2008;118:713–8.Search in Google Scholar

27. Kawamori R, Imano E, Watarai T, Nishizawa H, Matsushima H, et al. Platelet activation in diabetic patients with asymptomatic atherosclerosis. Diabetes Res Clin Pract 1994;24:89–95.10.1016/0168-8227(94)90025-6Search in Google Scholar

28. Sachais BS, Turrentine T, Dawicki McKenna JM, Rux AH, Rader D, et al. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE^-/- mice. Thromb Haemost 2007;98:1108–13.10.1160/TH07-04-0271Search in Google Scholar

29. Widhalm K, Strobl W, Sinzinger H. Effect of body weight reduction on platelet function and serum lipoproteins in obese children. Monatsschr Kinderheilkd 1981;129:623–6.Search in Google Scholar

30. Xu Y, Xu M, Bi Y, Song A, Huang Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011;216:180–6.10.1016/j.atherosclerosis.2011.01.020Search in Google Scholar PubMed

31. Ismail NA, Ragab S, El Dayem SM, Elbaky AA, Salah N, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci 2012;8:826–33.10.5114/aoms.2012.31616Search in Google Scholar PubMed PubMed Central

32. Hizli S, Abacı A, Özdemir O, Akelma Z, Akın O. Relation of fetuin A levels with cardiac, subcutaneous lipid accumulation and insulin resistance parameters in Turkish obese children. J Ped Endoc Metab 2016;29:669–73.Search in Google Scholar

33. João CE, Valezi AC, Delfino VD, Lavado EL, Barbosa DS. Reduction in plasma levels of inflammatory and oxidative stress indicators after Roux-en-Y gastric bypass. Obes Surg 2010;20:42–9.10.1007/s11695-009-9988-2Search in Google Scholar PubMed

34. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2007;27:352–8.10.1161/01.ATV.0000254150.97741.feSearch in Google Scholar PubMed

35. Cardoso-Saldaña G, Juárez-Rojas JG, Zamora-González J, Raygoza-Pérez M, Martinez-Alvarado R, et al. C-Reactive protein levels and their relationship with metabolic syndrome and insulin resistance in mexican adolescents. J Ped Endoc Metab 2007;20:797–806.10.1515/JPEM.2007.20.7.797Search in Google Scholar

Received: 2016-4-6

Accepted: 2016-8-29

Published Online: 2016-10-18

Published in Print: 2016-11-1

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jpem-2016-0136

Keywords for this article

fetuin-A; haptoglobin; α2-macroglobulin; metabolic syndrome; platelet factor-4; serum amyloid P